Vyxeos Approval History
FDA Approved: Yes (First approved August 3, 2017)
Brand name: Vyxeos
Generic name: cytarabine and daunorubicin
Dosage form: Injection
Company: Jazz Pharmaceuticals plc
Treatment for: Acute Myeloid Leukemia
Vyxeos (cytarabine and daunorubicin liposome injection) is a liposomal combination of cytarabine, a nucleoside metabolic inhibitor, and daunorubicin, an anthracycline topoisomerase inhibitor, indicated for the treatment of adults with newly-diagnosed therapy-related
acute myeloid leukemia (t-AML) or AML with myelodysplasia-related
changes (AML-MRC).
Development History and FDA Approval Process for Vyxeos
| Date | Article |
|---|
| Aug 3, 2017 |  FDA Approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia |
| May 31, 2017 | Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status |
| Apr 3, 2017 | Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia |
| Oct 3, 2016 | Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 2017 |
| May 19, 2016 | Celator Pharmaceuticals Announces Vyxeos Granted Breakthrough Therapy Designation |
| Mar 14, 2016 | Celator Announces Phase 3 Trial for Vyxeos™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival |
| Dec 11, 2012 | Celator Pharmaceuticals Announces Data on the Effects of CPX-351 in High Risk AML Presented at the ASH Annual Meeting |
| Jun 5, 2012 | Celator Pharmaceuticals Announces Presentations of Positive Survival Analyses from CPX-351 Studies at ASCO Annual Meeting |
| Dec 12, 2011 | Celator Pharmaceuticals and the Leukemia & Lymphoma Society Announce Positive Data from Phase 2b Study of CPX-351 at the American Society of Hematology Annual Meeting |
| Dec 7, 2010 | Celator Pharmaceuticals Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Hematology Annual Meeting |
| Jun 7, 2010 | Celator Pharmaceuticals Announces Data on Remissions With CPX-351 Following Induction Failure |
| May 3, 2010 | Celator Pharmaceuticals Announces Positive Data From Phase 2 Study of CPX-351 in Acute Myeloid Leukemia |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
